Tongguo Shi | Cancer | Best Researcher Award

Published on by China Scientist

Dr. Tongguo Shi | Cancer | Best Researcher Award

Tongguo Shi is an Associate Researcher at the First Affiliated Hospital of Soochow University, specializing in cancer immunology and molecular medicine. He earned his PhD from Nanjing University in 2016 and has since focused on tumor immune evasion, immune checkpoint regulation, and colorectal cancer research. His work has been published in leading journals such as Cancer Immunology, Immunotherapy and Cell Death & Disease, with multiple studies highlighting novel therapeutic targets. With expertise in molecular biology and immunological assays, he is dedicated to advancing cancer immunotherapy and precision medicine.

Dr. Tongguo Shi | The First Affiliated Hospital of Soochow University | China

Profile

SCOPUS ID

ORCID ID

🎓Education

  • Tongguo Shi earned his PhD from Nanjing University in 2016, following his undergraduate studies at Liyi University, where he obtained a BA in 2010. His academic journey has equipped him with a strong foundation in medical and biological research, particularly in immunology and oncology.

👨‍🏫Experience

  • Currently serving as an Associate Researcher at the First Affiliated Hospital of Soochow University, Tongguo Shi has been contributing to medical research since December 2021. Prior to this role, he worked as a Research Associate at the same institution from 2017 to 2021, where he gained extensive experience in cancer immunology and molecular medicine. He also served as a Research Associate at the Center of Systems Medicine, Chinese Academy of Medical Sciences, from 2016 to 2017, further strengthening his expertise in cellular and molecular research.

🏆Awards and Recognitions

  • Throughout his career, Tongguo Shi has established himself as a leading researcher, contributing significantly to cancer immunotherapy and colorectal cancer studies. His role as a corresponding author in multiple high-impact journal publications highlights his expertise and recognition in the scientific community. His work on immunological mechanisms in cancer and inflammatory diseases has been widely cited, demonstrating the impact of his research.

💡Skills and Certifications

  • Tongguo Shi specializes in immuno-oncology, with a focus on tumor microenvironments, immune evasion mechanisms, and cancer immunotherapy. His research has explored the role of immune checkpoints such as B7-H3 and Tim-3 in colorectal and gastric cancers, as well as the impact of microRNAs on immune regulation in inflammatory diseases. His skills include molecular biology techniques, immunological assays, cancer cell signaling analysis, and translational research aimed at developing novel therapeutic strategies.

🔬 Research Focus

  • His research has led to groundbreaking findings on the interactions between immune cells and cancer cells, with a particular emphasis on T cell-mediated immune responses. He has published extensively in prestigious journals such as Cancer Immunology, Immunotherapy, Cell Death & Disease, Mucosal Immunology, and Gut, further advancing the understanding of cancer immunology and potential therapeutic interventions.

🌎Conclusion

  • Dr. Tongguo Shi exemplifies scientific excellence and collaborative leadership in cancer research. His work has significantly advanced the understanding of tumor immunology, cancer metabolism, and immunotherapy through high-impact interdisciplinary collaborations. His strong publication record, mentorship, and institutional partnerships highlight his commitment to groundbreaking discoveries that benefit both scientific progress and patient outcomes.

📖Publications

  • Elevated SPARC Disrupts the Intestinal Barrier Integrity in Crohn’s Disease by Interacting with OTUD4 and Activating the MYD88/NF‐κB Pathway
    Authors: J. Wang, Jiayu; Y. He, Yuxin; X. Zhu, Xingchao; J. Zhu, Jinghan; Z. Deng, Zilin; H. Zhang, Huan; Y. Chen, Yanjun; G. Zhang, Guangbo; T. Shi, Tongguo; W. Chen, Weichang
    Journal: Advanced Science, 2025

  • FASN Promotes Lipid Metabolism and Progression in Colorectal Cancer via the SP1/PLA2G4B Axis
    Authors: X. Liu, Xin; J. Lu, Jiachun; X. Ni, Xiangyu; Y. He, Yuxin; J. Wang, Jiayu; Z. Deng, Zilin; G. Zhang, Guangbo; T. Shi, Tongguo; W. Chen, Weichang
    Journal: Cell Death Discovery, 2025

  • Exploring the Link Between Noncoding RNAs and Glycolysis in Colorectal Cancer
    Authors: L. Xu, Liang; Y. Shen, Yu; C. Zhang, Chuanqiang; T. Shi, Tongguo; X. Sheng, Xuejuan
    Journal: Journal of Cellular and Molecular Medicine, 2025

  • The m6A Revolution: Transforming Tumor Immunity and Enhancing Immunotherapy Outcomes
    Authors: T. Shi, Tongguo; H. Zhang, Huan; Y. Chen, Yueqiu
    Journal: Cell & Bioscience, 2025

  • Exosome-Derived Proteins in Gastric Cancer Progression, Drug Resistance, and Immune Response
    Authors: J. Wang, Jiayu; H. Zhang, Huan; J. Li, Juntao; X. Ni, Xiangyu; W. Yan, Wenying; Y. Chen, Yueqiu; T. Shi, Tongguo
    Journal: Cellular & Molecular Biology Letters, 2024

Zongzhi Liu | Bioinformatics | Best Researcher Award

Published on by China Scientist

Assoc Prof Dr.Zongzhi Liu | Bioinformatics | Best Researcher Award

Successful Research Projects:
  • Dr. Liu has led significant projects, including the study of RUNX3 methylation’s impact on T cell function and immunotherapy response. His successful acquisition of funding for multiple National Natural Science Foundation projects reflects his ability to secure resources for impactful research.
Assoc Prof Dr. Zongzhi Liu , Changping Laboratory, China

Profile

Scopus

🏛️Early Academic Pursuits

  • Zongzhi Liu’s academic journey is deeply rooted in the exploration of human diseases and immunotherapy. His early academic work laid the foundation for his current focus on the mechanisms of neurodegenerative diseases and tumor immunotherapy. By leveraging next-generation sequencing and bioinformatics, he has significantly contributed to the understanding of disease pathways and therapeutic targets.

👨‍🔬  Professional Endeavors

  • Liu’s professional endeavors are characterized by his commitment to precision medicine and epigenetic research. His notable projects include the development of epigenetic biomarkers for early cancer diagnosis and targeted therapy. His work with Runx3 knockout mouse models has provided critical insights into the epigenetic regulation of PD-1 tumor treatment response and resistance.

🔬 SCADEN Algorithm and Neurodegenerative Diseases

  • Liu utilized the SCADEN algorithm to predict primary pathways involved in neuron degeneration, specifically focusing on Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and Amyotrophic Lateral Sclerosis (ALS). His research integrates behavioral experiments in mice to explore these mechanisms further.

🧫 Multi-Omics Analysis for Tumor Immunotherapy

  • Through multi-omics analysis, Liu identified epigenetic targets for tumor immunotherapy. His establishment of a Runx3 knockout mouse model was pivotal in demonstrating that Runx3 epigenetic reprogramming is a key regulator of PD-1 tumor treatment response and resistance.

🌐 Research and Innovations

  • Liu’s innovations extend to several high-impact projects:

    • Molecular Mechanism of T Cell Function: Studied the regulation of T cell function related to RUNX3 methylation reprogramming, funded by the National Natural Science Foundation (2023-2025).
    • Emerging Infectious Diseases: Contributed to pathogen identification and early warning technology for infectious diseases, as part of a national task (2021-2024).
    • Combined Immunotherapy: Investigated the synergistic effects of combined immunotherapy, with significant clinical implications (2016-2022).
    • Maternal Age and Pregnancy Outcomes: Explored the impact of advanced maternal age on pregnancy outcomes and offspring health (2018-2022).
    • Liquid Biopsy Technology: Evaluated liquid biopsy technology for early cancer screening and diagnosis (2019-2021).

🏢 Consultancy/Industry Projects

  • National Natural Science Foundation Project: Molecular mechanism study on T cell function regulation (2023-2025).
  • National Task Project: Study on pathogen identification and early warning technology (2021-2024).
  • National Key R&D Program: Research on combined immunotherapy (2016-2022).
  • National Natural Science Foundation Key Project: Impact of advanced maternal age on pregnancy outcomes (2018-2022).
  • Ministry of Science and Technology Key R&D Program: Liquid biopsy technology for early cancer diagnosis (2019-2021).

🌍 Impact and Influence

  • Liu’s research has significantly impacted the fields of neurodegenerative diseases and tumor immunotherapy. His work on epigenetic reprogramming and precision medicine has paved the way for innovative approaches to early diagnosis and targeted therapy, influencing both clinical practices and future research directions.

👩‍🔬 Professional Memberships AND Collaborations

  • Zongzhi Liu holds esteemed editorial appointments as a reviewer for Frontiers in Oncology and Frontiers in Pediatrics, contributing his expertise to the peer-review process. His collaborative efforts span multiple prestigious institutions, including the General Hospital of the People’s Liberation Army of China, the Institute of Pathogen Biology at the Chinese Academy of Medical Sciences, Peking University Third Hospital, and the Cancer Hospital of the Chinese Academy of Medical Sciences. As a member of the Chinese Society for Cell Biology, Liu actively participates in advancing the field of bioinformatics in human diseases. His research focuses on bioinformatics, with a particular interest in the mechanisms of neurodegenerative diseases and tumor immunotherapy, underscoring his commitment to the intersection of epigenetics and precision medicine.

🌟 Legacy and Future Contributions

  • Liu’s legacy in the scientific community is marked by his groundbreaking research and dedication to advancing medical science. His future contributions are anticipated to further enhance our understanding of disease mechanisms and therapeutic strategies, ultimately improving patient outcomes and shaping the future of precision medicine.

📄Publications

  • Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy
    • Authors: Liu, Z., Li, X., Gao, Y., Mei, Q., Sun, Y.
    • Journal: Molecular Cancer, 2023, 22(1), 84
  • CRISPR-Cas13d effectively targets SARS-CoV-2 variants, including Delta and Omicron, and inhibits viral infection
    • Authors: Liu, Z., Gao, X., Kan, C., Zhang, Z., Sun, Y.
    • Journal: MedComm, 2023, 4(1), e208
  • Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
    • Authors: Jing, C., Wang, J., Zhu, M., Zhang, Z., Deng, W.
    • Journal: Cancer Immunology, Immunotherapy, 2022, 71(11), pp. 2597–2608
  • Whole-genome circulating tumor DNA methylation landscape reveals sensitive biomarkers of breast cancer
    • Authors: Hai, L., Li, L., Liu, Z., Tong, Z., Sun, Y.
    • Journal: MedComm, 2022, 3(3), e134
  • Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
    • Authors: Wang, Y., Tong, C., Dai, H., Zhang, Y., Han, W.
    • Journal: Nature Communications, 2021, 12(1), 409